SAN DIEGO and RALEIGH-DURHAM, N.C., June 12, 2012 /PRNewswire/ -- Synteract, Inc., a full-service contract research organization (CRO), will unveil its new branding at this year's Drug Information Association (DIA) annual meeting to be held from June 24-28 in Philadelphia at the Pennsylvania Convention Center. Synteract will exhibit in booth #1925. The company has revamped its brand to better showcase the full range of Phase I-IV services and expertise it offers biotechnology, medical device, and pharmaceutical companies.
While the company's tagline – Shared Work-Shared Vision™ – has not changed, it has been enhanced by additional messaging that helps to define Synteract's updated commercial strategy and strong partnership approach. The company has evolved and expanded its service offering, scale and reach in response to client demand. The new brand platform serves to reinforce that updated perspective on Synteract to the industry. The company used images of its own people in its marketing because they are the cornerstone of the global clinical development and industry expertise supporting clients every day.
The company's continued growth on the East Coast in Research Triangle Park and in Europe has been a driver for the revamped brand identity, according to Synteract CEO Wendel Barr. "Our updated brand position reflects the evolution and growth Synteract has achieved through our commitment to serving the unique needs of emerging to midsize biotech and pharma. Our high rate of repeat business is a testament to our success, as is our support of 22 product approvals. It's the commitment of our employees that has sustained our growth as well as that of our clients. Our continued dedication to great partnerships will be more clearly communicated through this revised messaging and strong visual identity that focuses on our people – they are Synteract."
As part of its strategy, the company is hiring to augment its medical, clinical, biostatistics and regulatory expertise and has increased its sales and marketing investment as well. The refocused brand identity includes a fully revamped website and tradeshow booths, increased advertising, public relations and social media efforts. Synteract's leaders are actively engaged in front of the medical, scientific and business communities through speaking engagements, contributed articles and interaction with industry associations and standards bodies such as CDISC, SCDM, DIA and others.
Barr added, "The new brand platform allows Synteract to more clearly address our differentiators within this competitive industry, giving current and prospective clients an overview of our customized approach and longstanding clinical development experience to facilitate their search for an outsourcing partner to match their specific needs. And as we move forward with European acquisition plans later this year, we want our culture to be clear."
At DIA, Synteract's growing team of drug development experts will be available to discuss the company's clinical development expertise. To set up an appointment in advance, contact Matt Smith, SVP Sales and Marketing at 760-795-2149 or email@example.com. The company will also host a reception at its booth on Monday, June 25th, 4:00 p.m.
About Synteract (www.synteract.com)
Synteract is a full-service contract research organization with a successful 17-year track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. With its "Shared Work – Shared Vision" philosophy Synteract provides customized Phase I through IV services collaboratively and cost effectively to ensure on-time delivery of quality data so clients get to decision points faster. Headquartered in California, with offices in North Carolina and the Czech Republic, Synteract delivers trials internationally, offering expertise across multiple therapeutic areas including notable depth in oncology, CNS, cardiovascular, respiratory and ophthalmology.
Clearpoint Agency, for Synteract
SOURCE Synteract, Inc.